Revenue Update on Entellus Medical Inc(NASDAQ:ENTL)

Entellus Medical Inc(NASDAQ:ENTL) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 3, 2016. Company reported revenue of $18.73M. Analysts estimated a revenue of $18.48M. Earnings per share were $-0.27. Analysts had estimated an EPS of $-0.35.

In a different note, BTIG Research said it Initiates Coverage on Entellus Medical Inc, according to a research note issued on Jun 14, 2016. The shares have been rated ‘Buy’ by the firm.

Entellus Medical Inc (ENTL) shares turned negative on Fridays trading session with the shares closing down -0.22 points or -1.20% at a volume of 25,260. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $18.44. The peak price level was also seen at $18.44 while the days lowest was $18.05. Finally the shares closed at $18.13. The 52-week high of the shares is $23.83 while the 52-week low is $13.72. According to the latest information available, the market cap of the company is $342 M.

Several Insider Transactions has been reported to the SEC. On Aug 2, 2016, Kevin L Mensink (Vice President, Marketing) sold 8,100 shares at $17.63 per share price.Also, On Jul 19, 2016, Timothy B Petrick (VP, Research and Development) sold 3,000 shares at $18.15 per share price.On Feb 4, 2016, Karen E Peterson (officer ) sold 10,000 shares at $17.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Entellus Medical Inc. is a medical technology company. The Company is focused on the design development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. Its XprESS family of products includes its XprESS Pro device its XprESS LoProfile device and its XprESS Ultra device. The Company markets its products in the United States and Canada and sells its products through a direct sales force in the United States.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Entellus Medical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Entellus Medical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.